Hyperuricemia, chronic kidney disease
Conditions
Interventions
Febuxostat 10-60 mg/day to target serum urate range from 4 to 6 mg/dL from the baseline to 48 weeks
Conventional treatments (allopurinol and/or benzbromarone, or no drug) to target serum urate range f
Sponsors
Division of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Obtained written informed consent from the patient for the study participation 2) Stable condition for more than 3 months on the treatments by a nephrologist 3) Age >-20 and <80 years old 4) eGFR >-15 and <45 mL/min/1.73m2 5) Serum uric acid >-7.0 mg/dL and <11.0 mg/dL 6) Urinary protein creatinine ratio >-0.3 and <3.5 g/gCr 7) Outpatient who can visit bimonthly at least
Exclusion criteria
Exclusion criteria: 1) High-risk patients requiring dialysis or renal transplantation within 48 weeks 2) History of gout 3) Patients with Cancer or liver disease (HBV/HCV hepatitis, cirrhosis, and the other liver injuries showing AST/ALT values more than twice as high of normal values 4) HbA1c (JDS) >-7.0% with 2 months prior to the entry 5) Office systolic blood pressure >-160 mmHg or diastolic blood pressure >-100 mmHg both at recent twice office visits before the entry 6) Severe heart failure or edema 7) History of renal replacement therapy 8) History of febuxostat intake within four weeks before the entry 9) History of hypersensitivity to allopurinol, benzbromarone, or febuxostat 10) Judged as ineligible in the opinion of the attending physician 11) Pregnancy or nursing
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary protein creatinine ratio at 24 weeks after treatments | — |
Secondary
| Measure | Time frame |
|---|---|
| Chronological changes of urinary protein excretion from the baseline to 24 weeks and those from 24 to 48 weeks. Estimated GFR, plasma renin activity, plasma aldosterone concentration, urinary albumin creatinine ratio, urinary L-FABP, urinary 8-OHdG, serum methylglyoxal, and blood pressure | — |
Countries
Japan
Contacts
Public ContactTakashi Nakamichi
Tohoku University Graduate School of Medicine Division of Nephrology, Endocrinology, and Vascular Medicine
Outcome results
None listed